poisar

Stocks · News reference

BioNexus Gene Lab Announces $3.5M All-Stock Deal For Exclusive 10-Year Malaysian Healthcare License To Ruanyun Edai's CogniAI Platform

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BGLC
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — BioNexus Gene Lab Corp (BGLC)

    Filed: 2026-10-07 AccNo: 0001477932-26-006075 Size: 247 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    BGLC
  2. Na

    RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab

    Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.

    RYETBGLC